Despite the ranking of SRC and LCK as Top2 pY-kinases in most lines (Fig. 1b and Supplementary Fig. 2a, b), only HSB-2 and ALL-SIL cells were highly sensitive to ATP-competitive SRC/ABL inhibitors (dasatinib, ponatinib, bosutinib, nilotinib, and imatinib) with IC50 values below 100 nM. Here, ABL1 is linked to acute lymphoblastic leukemia.